1. Home
  2. CMPS vs DCTH Comparison

CMPS vs DCTH Comparison

Compare CMPS & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo COMPASS Pathways Plc American Depository Shares

CMPS

COMPASS Pathways Plc American Depository Shares

HOLD

Current Price

$9.62

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$11.31

Market Cap

363.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMPS
DCTH
Founded
2020
1988
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
363.5M
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
CMPS
DCTH
Price
$9.62
$11.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
4
Target Price
$25.38
$22.00
AVG Volume (30 Days)
5.6M
327.1K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
107.53
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$24.54
Revenue Next Year
N/A
$33.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.25
$8.12
52 Week High
$10.21
$18.23

Technical Indicators

Market Signals
Indicator
CMPS
DCTH
Relative Strength Index (RSI) 62.96 58.23
Support Level $5.95 $10.17
Resistance Level $10.21 $11.99
Average True Range (ATR) 0.71 0.54
MACD 0.05 0.03
Stochastic Oscillator 79.84 54.50

Price Performance

Historical Comparison
CMPS
DCTH

About CMPS COMPASS Pathways Plc American Depository Shares

Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: